99% Apixaban CAS 503612-47-3

Sharaxaad Gaaban:

Magaca kiimikada:Apixaban
Magac kale:1- (4-Methoxyphenyl) -7-oxo-6- (4- (2-oxopiperidin-1-yl) phenyl) -4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine -3-carboxaMide;1- (4-Methoxyphenyl)-7-oxo-6-[4- (2-oxopiperidin-1-yl) phenyl]-4,
5-dihydropyrazolo[3,4-c]pyridine-3-carboxaMide
Lambarka CAS:503612-47-3
daahirnimo99% min
Formula:C25H25N5O4
Miisaanka Molecular:459.50
Guryaha Kiimikada:Apixaban waa budo crystalline cad.Waa nooc cusub oo afka ah Xa factor inhibitor, magaceeduna ganacsi waa Eliquis.Apixaban waxaa loo isticmaalaa in lagu daaweeyo bukaanada qaangaarka ah ee lagu sameeyo qalliinka beddelka miskaha ama jilibka si looga hortago xinjirowga dhiigga (VTE).

Email noogu soo dir

Faahfaahinta Alaabta

Tags Product

Tilmaamid

ITEM	HEERKA
Muuqashada	Caddaan ilaa caddaan adag
daahirnimo	≥ 99%

Codsiga

Apixaban waa nooc cusub oo ah daawada xinjirowga lidka ku ah afka, nooc cusub oo afka laga qaato Xa inhibitor, kaas oo loo isticmaalo ka hortagga iyo daaweynta xinjirowga dhiigga.
Apixaban waa cunsur cusub oo afka laga qaato Xa inhibitor oo ay si wadajir ah u soo saareen Bristol-Myers Squibb iyo Pfizer.Iyadoo la xakameynayo xinjirowga muhiimka ah ee Xa, apixaban waxay ka hortagtaa jiilka thrombin iyo xinjirowga dhiigga.

Bishii Abriil 26, 2007, Bristol-Myers Squibb iyo Pfizer waxay ku dhawaaqeen horumarinta wadajirka ah ee apixaban cusub ee daawada xinjirowga lidka ku ah afka oo ay iska leedahay Bristol-Myers Squibb si ay u noqoto beddelka warfarin oo la cusboonaysiiyay.
Bishii Maajo 2011, apixaban ayaa ahayd tii ugu horreysay ee loo oggolaado ka hortagga xinjirowga dhiigga ee bukaannada qaangaarka ah ee lagu sameynayo qalliinka beddelka miskaha ama jilibka ee la doortay ee 27 dalalka EU, Iceland iyo Norway.
Bishii Noofambar 20, 2012, Komishanka Yurub wuxuu ansixiyay ELIQUIS (apixaban) si looga hortago istaroogga iyo embolism nidaamka ee dadka qaangaarka ah ee qaba fibrillation aan valvular ahayn (NVAF) oo leh hal ama dhowr arrimood oo halis ah.
Maamulka Cuntada iyo Dawooyinka ee Kanadiyaanka, Japan, iyo Maamulka Cuntada iyo Dawooyinka ee Maraykanka ayaa markii dambe ansixiyay ELIQUIS (apixaban) ee ka hortagga istaroogga iyo embolism systemic ee dadka qaangaarka ah ee qaba fibrillation aan valvular ahayn (NVAF) oo leh hal ama dhowr arrimood oo halis ah.
Abriil 12, 2013, ELIQUIS (Apixaban), ayaa si rasmi ah loogu dhawaaqay suuqa Shiinaha.Apixaban waa arrin cusub oo afka ah Xa inhibitor ee ka hortagga xinjirowga xididada xididada (VTE) ee bukaanada qaangaarka ah ee maraya qalliinka beddelka miskaha ama jilibka.Daahfurkeedu wuxuu bixiyaa doorasho cusub oo ammaan ah oo wax ku ool ah oo loogu talagalay ka hortagga xinjirowga lidka ku ah ka dib qalliinka lafaha ee waxqabadka kiliinikada, waxayna u keentaa war wanaagsan bukaannada Shiinaha ee maraya beddelka miskaha/jilibka ee la doortay.
Daraasadaha kiliinikada ayaa xaqiijiyay in marka la barbar dhigo 40 mg cirbadeynta subcutaneous ee enoxaparin hal mar maalintii, 2.5 mg ELIQUIS (Apixaban) afka laba jeer maalintii ayaa aad waxtar u leh ka hortagga dhacdooyinka xinjirowga dhiigga ka dib qalliinka beddelka miskaha ama jilibka, mana kordhiso halista dhiigbax.